The CD69+-high group had more patients with AML-M0 subtypes (TARGET, 9.5% vs. 2.7%, p = 0.092; TCGA, 23.5% vs. 2.2%, p = 0.004), while the CD69+-low group was enriched for AML-M2/M4 subtypes (TARGET, 56.4% vs. 19.1%, p = 0.000; TCGA, 44.5% vs. 23.6%, p = 0.062, Table 1). Here, CD69 is linked to acute myeloid leukemia.